Recently, the Ministry of Industry and Information Technology (MIIT) has released the list of entities selected for the high-performance bioreactor innovation project. The Trautec Medical Technology Co., Ltd. will join hands with Tsinghua University and CytoNiche to carry out research focusing on the task of large-scale preparation of cell-culture microcarriers.

As the project aims to enhance integrated innovation and biomanufacturing capabilities, the MIIT and the Chinese Academy of Sciences has established an open bidding mechanism to select the best candidates.

The project breaks down to nine tasks. Trautec is the only candidate from Changzhou. The company will supply core materials to the project - the design and development of recombinant type-I collagen. At present, Trautec has designed and developed a highly-stable, highly-adhesive, and easily processable recombinant type-I collagen, which is 100% human-derived. The related raw materials have already been granted invention patents.

Trautec, headquartered in Jintan District, is recognized as a national-level "Little Giant" enterprise specializing in high-tech and high-growth sectors. Through advanced bio-fermentation technologies, the company has achieved large-scale production of multiple types of recombinant collagen— including Type I, II, III, and others— as well as biomaterials such as nucleic acid tetrahedrons. Its recombinant collagen raw materials rank among the world's top sellers.

扫一扫在手机打开当前页